Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24

Roshan A. Karunamuni¹, Minh-Phuong Huynh-Le², Chun C. Fan³, Wesley Thompson⁴, Asona Lui¹, Maria Elena Martinez^{5,6}, Brent S. Rose¹, Brandon Mahal⁷, Rosalind A. Eeles^{8,9}, Zsofia Kote-Jarai⁸, Kenneth Muir^{10,11}, Artitaya Lophatananon¹⁰, UKGPCS collaborators¹², Catherine M. Tangen¹³, Phyllis J. Goodman¹³, Ian M. Thompson Jr.¹⁴, William J. Blot^{15,16}, Wei Zheng¹⁵, Adam S. Kibel¹⁷, Bettina F. Drake¹⁸, Olivier Cussenot^{19,20}, Géraldine Cancel-Tassin^{20,19}, Florence Menegaux²¹, Thérèse Truong²¹, Jong Y. Park²², Hui-Yi Lin²³, Jack A. Taylor^{24,25}, Jeannette T. Bensen^{26,27}, James L. Mohler^{28,27}, Elizabeth T.H. Fontham²⁹, Luc Multigner³⁰, Pascal Blanchet³¹, Laurent Brureau³¹, Marc Romana^{32,33}, Robin J. Leach³⁴, Esther M. John³⁵, Jay H. Fowke^{36,37}, William S. Bush³⁸, Melinda C. Aldrich³⁹, Dana C. Crawford⁴⁰, Jennifer Cullen⁴¹, Gyorgy Petrovics^{42,43}, Marie-Élise Parent^{44,45}, Jennifer J. Hu⁴⁶, Maureen Sanderson⁴⁷, Ian G. Mills⁴⁸, Ole A. Andreassen⁴⁹, Anders M. Dale⁵⁰, Tyler M. Seibert^{1,50,51}, The PRACTICAL Consortium⁵²

Table of Contents

3
6
9
12
13
14
15
16
21

Supplemental Table 1 Local neighborhood SNP window. RS number, chromosome, position (version 37), effect allele, reference allele and effect allele frequency in Africans from the 1000G dataset for the 93 SNPs that constitute 8q24 SNP window.

DS number	Chromosome	Docition	Position Effect		Effect Allele
RS number	o number Chiomosome Position		Ellect	Reference	Frequency
rs958653	8	128070669	G	А	0.072
rs9297751	8	128070847	С	Т	0.386
rs34241583	8	128070900	Α	G	0.209
rs10505485	8	128071064	G	Α	0.272
rs9649957	8	128071305	Т	С	0.290
rs58120361	8	128071380	Т	С	0.434
rs62529863	8	128071464	Т	С	0.385
rs17763940	8	128071504	Α	G	0.012
rs6983515	8	128071922	Α	G	0.467
rs7833560	8	128072019	С	Т	0.467
rs7003994	8	128072064	С	Т	0.023
rs1456314	8	128075690	Α	G	0.530
rs16901935	8	128076545	G	Α	0.047
rs77541621	8	128077146	Α	G	0.000
rs12542102	8	128077521	С	Т	0.653
rs2392729	8	128079666	Т	С	0.039
rs77120121	8	128079697	Т	С	0.036
rs7824674	8	128081093	G	Α	0.097
rs7824923	8	128081138	Т	С	0.097
rs7825394	8	128081449	Т	С	0.097
rs61386925	8	128083486	G	Α	0.058
rs6993569	8	128084097	Α	G	0.489
rs6994316	8	128084539	G	Α	0.206
rs76229939	8	128085394	G	Α	0.048
rs114798100	8	128085434	G	Α	0.048
rs11998248	8	128085755	Α	G	0.483
rs35450468	8	128086032	G	Α	0.489
rs74634260	8	128086189	С	Α	0.002
rs76595456	8	128087829	Т	С	0.115
rs6470494	8	128087904	Т	С	0.292
rs7843737	8	128088066	Α	G	0.293
rs75500912	8	128089536	С	Α	0.081
rs4581008	8	128090865	Т	С	0.281
rs36002700	8	128091158	G	Т	0.157
rs12544839	8	128091382	Α	G	0.328
rs72725868	8	128091418	G	Α	0.004

rs10956351	8	128091	559 G	Α	0.581
rs1016342	8	128092	455 T	С	0.676
rs73705708	8	128092	911 G	Α	0.141
rs1031589	8	128092	982 G	Α	0.284
rs1031588	8	128093	277 A	С	0.026
rs1016343	8	128093	297 T	С	0.210
rs4871008	8	128093	541 T	С	0.284
rs7001504	8	128094	483 T	G	0.284
rs13252298	8	128095	156 G	Α	0.030
rs73705712	8	128095	977 G	Α	0.117
rs74421890	8	128096	183 T	С	0.042
rs59765225	8	128099	765 G	Α	0.168
rs9656814	8	128100	977 T	С	0.125
rs11994653	8	128101	343 G	Α	0.656
rs7000321	8	128103	019 C	Α	0.214
rs1456315	8	128103	937 T	С	0.581
rs5013678	8	128103	979 C	Т	0.081
rs118005113	8	128104	745 A	С	0.001
rs1073997	8	128105	187 C	Α	0.470
rs57775023	8	128105	672 A	G	0.077
rs7016830	8	128106	235 G	Α	0.465
rs115266272	8	128106	397 A	G	0.033
rs6983561	8	128106	880 C	Α	0.526
rs16901949	8	128107	153 C	Α	0.371
rs60681470	8	128107	192 A	G	0.504
rs16901950	8	128107	243 A	G	0.370
rs16901952	8	128107	270 C	Т	0.370
rs16901953	8	128108	229 C	Т	0.381
rs146278672	8	128108	324 T	С	0.033
rs35365584	8	128108	726 A	G	0.098
rs17832285	8	128108	993 G	Α	0.092
rs7825340	8	128109	129 G	Α	0.091
rs12544977	8	128109	287 A	G	0.198
rs73344342	8	128109	356 A	G	0.380
rs16901959	8	128109	530 G	Α	0.381
rs7826337	8	128109	574 A	G	0.616
rs7826388	8	128109	776 T	С	0.209
rs7830341	8	128109	930 A	G	0.380
rs16901966	8	128110	252 G	Α	0.381
rs16901967	8	128110	277 G	Α	0.379
rs7001069	8	128110	646 G	Α	0.380
rs11781162	8	128110	896 G	Α	0.001
rs73348236	8	128111	470 T	С	0.380

rs57010632	8	128111717	G	Α	0.531
rs16901969	8	128112097	С	Α	0.380
rs61265543	8	128112446	Т	С	0.531
rs16901970	8	128112715	G	Т	0.381
rs10453084	8	128112779	Α	G	0.380
rs6987723	8	128112859	Α	G	0.380
rs113694160	8	128112976	Α	G	0.002
rs7824785	8	128114710	Т	С	0.379
rs73348257	8	128115259	Α	G	0.379
rs75170735	8	128115378	G	Α	0.001
rs28686871	8	128116480	Т	G	0.032
rs1456306	8	128116500	Α	G	0.106
rs57462547	8	128117863	Т	С	0.535
rs7844219	8	128118815	G	Α	0.536

Supplementary Table 2. Interaction term between 8q24 PC and PHS46+African. P-values of the coefficient associated with the interaction term between 8q24 principal components and PHS46+African (β_2 from Equation 1) are tabulated in ascending order. PC-1 and PC-20 (highlighted in gray) were associated with the two smallest p-values and therefore, selected for further analysis.

Dringing component	n value of 0 DC v DUC4C African
Principal component	. , =
1	1.06E-05
20	8.52E-05
90	1.34E-04
84	2.77E-04
56	5.64E-04
51	7.03E-04
93	1.63E-03
82	2.55E-03
78	6.06E-03
73	6.60E-03
31	9.85E-03
57	1.44E-02
11	1.82E-02
12	1.92E-02
71	2.65E-02
68	2.65E-02
38	3.51E-02
74	3.73E-02
8	3.75E-02
92	3.84E-02
65	3.98E-02
23	4.01E-02
14	4.14E-02
62	4.15E-02
88	4.73E-02
42	6.83E-02
69	7.04E-02
87	7.18E-02
53	7.70E-02
75	7.76E-02
85	8.41E-02
22	1.02E-01
79	1.19E-01

81	1.31E-01
2	1.32E-01
35	1.78E-01
24	1.85E-01
58	1.85E-01
83	2.09E-01
32	2.18E-01
9	2.28E-01
55	2.33E-01
41	2.55E-01
91	3.15E-01
13	3.18E-01
59	3.40E-01
66	3.73E-01
40	4.13E-01
72	4.23E-01
43	4.27E-01
18	4.29E-01
19	4.31E-01
63	4.32E-01
37	4.32E-01
3	4.42E-01
76	4.46E-01
6	4.62E-01
50	4.69E-01
60	4.94E-01
33	4.95E-01
70	5.13E-01
54	5.13E-01
36	5.17E-01
52	5.20E-01
27	5.37E-01
10	5.50E-01
16	5.53E-01
44	5.55E-01
61	5.69E-01
86	5.70E-01
77	5.97E-01
28	6.27E-01
29	6.39E-01

4	6.40E-01
39	6.45E-01
17	6.77E-01
30	6.85E-01
21	6.91E-01
26	6.92E-01
64	7.18E-01
25	7.31E-01
7	7.39E-01
80	7.76E-01
89	7.83E-01
48	7.86E-01
15	7.91E-01
5	8.69E-01
34	8.79E-01
46	8.80E-01
67	9.37E-01
47	9.47E-01
45	9.55E-01
49	9.66E-01

Supplementary Table 3. Estimating PC-1 and PC-20. Scaling factors and PC coefficients used to estimate PC-1 and PC-20 from the genetic counts of the 93-SNP 8q24 window.

	Scalin	g factor	Coefficients		
RS number	Mean	Std Dev	PC-1	PC-20	
rs958653	0.205	0.430	-0.026	-0.162	
rs9297751	0.732	0.684	-0.015	-0.087	
rs34241583	0.460	0.590	-0.007	0.057	
rs10505485	0.524	0.615	0.017	0.220	
rs9649957	0.647	0.657	0.001	0.156	
rs58120361	0.849	0.709	-0.002	0.036	
rs62529863	0.758	0.688	-0.016	0.061	
rs17763940	0.058	0.240	-0.031	0.043	
rs6983515	0.849	0.694	-0.030	-0.136	
rs7833560	0.856	0.704	-0.031	-0.139	
rs7003994	0.050	0.224	0.041	-0.092	
rs1456314	1.045	0.714	0.028	-0.067	
rs16901935	0.087	0.289	-0.015	0.348	
rs77541621	0.009	0.094	0.009	0.046	
rs12542102	1.223	0.697	0.037	-0.068	
rs2392729	0.180	0.410	-0.052	-0.027	
rs77120121	0.092	0.299	0.013	-0.073	
rs7824674	0.294	0.500	-0.055	-0.092	
rs7824923	0.293	0.499	-0.055	-0.093	
rs7825394	0.293	0.499	-0.055	-0.093	
rs61386925	0.154	0.379	-0.049	-0.223	
rs6993569	0.923	0.715	0.004	0.019	
rs6994316	0.411	0.575	0.019	-0.048	
rs76229939	0.125	0.341	0.002	0.011	
rs114798100	0.125	0.341	0.002	0.011	
rs11998248	0.900	0.714	-0.001	0.011	
rs35450468	0.922	0.715	0.004	0.018	
rs74634260	0.006	0.079	-0.008	0.151	
rs76595456	0.248	0.463	0.006	-0.060	
rs6470494	0.599	0.648	0.020	0.033	
rs7843737	0.583	0.642	0.013	0.038	
rs75500912	0.182	0.406	0.015	-0.102	
rs4581008	0.581	0.633	0.012	0.038	
rs36002700	0.266	0.481	-0.034	-0.055	
rs12544839	0.647	0.647	0.027	0.041	
rs72725868	0.024	0.156	-0.021	0.157	
rs10956351	1.104	0.694	0.005	-0.039	
rs1016342	1.293	0.675	-0.016	-0.040	

rs73705708	0.293	0.499	-0.001	-0.048
rs1031589	0.597	0.649	0.000	-0.025
rs1031588	0.132	0.356	-0.055	-0.010
rs1016343	0.431	0.589	0.030	0.063
rs4871008	0.597	0.649	0.000	-0.023
rs7001504	0.595	0.648	0.000	-0.025
rs13252298	0.123	0.348	-0.038	-0.097
rs73705712	0.196	0.422	0.012	-0.080
rs74421890	0.077	0.271	-0.016	-0.064
rs59765225	0.327	0.527	0.011	-0.011
rs9656814	0.334	0.530	-0.026	-0.039
rs11994653	1.204	0.696	-0.002	-0.001
rs7000321	0.457	0.591	0.032	0.072
rs1456315	1.150	0.696	0.090	0.064
rs5013678	0.178	0.396	-0.048	0.028
rs118005113	0.005	0.071	-0.008	-0.026
rs1073997	0.831	0.700	0.180	0.005
rs57775023	0.211	0.434	-0.060	0.038
rs7016830	0.824	0.700	0.182	-0.006
rs115266272	0.103	0.311	-0.011	0.047
rs6983561	0.988	0.705	0.167	0.026
rs16901949	0.686	0.657	0.192	0.008
rs60681470	0.931	0.708	0.174	0.009
rs16901950	0.665	0.666	0.193	-0.001
rs16901952	0.670	0.667	0.194	-0.002
rs16901953	0.685	0.671	0.196	-0.015
rs146278672	0.103	0.311	-0.011	0.046
rs35365584	0.240	0.460	-0.068	-0.016
rs17832285	0.194	0.418	-0.060	0.012
rs7825340	0.206	0.429	-0.059	0.054
rs12544977	0.406	0.570	-0.085	-0.019
rs73344342	0.681	0.670	0.195	-0.015
rs16901959	0.685	0.671	0.196	-0.016
rs7826337	1.179	0.693	0.138	-0.010
rs7826388	0.393	0.564	0.138	0.012
rs7830341	0.680	0.670	0.195	-0.016
rs16901966	0.683	0.671	0.196	-0.017
rs16901967	0.683	0.671	0.196	-0.017
rs7001069	0.683	0.671	0.196	-0.017
rs11781162	0.007	0.082	-0.010	0.265
rs73348236	0.683	0.671	0.196	-0.017
rs57010632	0.997	0.703	0.170	0.007
rs16901969	0.676	0.672	0.195	-0.018

rs61265543	0.987	0.711	0.172	-0.005
rs16901970	0.683	0.671	0.196	-0.016
rs10453084	0.683	0.671	0.196	-0.017
rs6987723	0.680	0.670	0.195	-0.016
rs113694160	0.009	0.094	-0.013	-0.378
rs7824785	0.682	0.671	0.196	-0.017
rs73348257	0.683	0.670	0.196	-0.016
rs75170735	0.101	0.434	0.001	0.528
rs28686871	0.098	0.307	-0.042	0.011
rs1456306	0.238	0.459	-0.066	-0.017
rs57462547	0.988	0.711	0.170	-0.004
rs7844219	0.989	0.711	0.170	-0.003

Supplementary Table 4. Predicted dataset variables by calibration group. Predicted mean value of dataset variables (case-rate, age of cases, and genetic count of 8q24 SNPs) for each calibration group using generalized linear models. Table values marked with asterisks are significantly different (p<0.05) than the corresponding value for the low-performing 2-PC region.

Calibration	Case-	Age of	Genetic count		
group	fraction	Cases	rs76229939	rs74421890	rs5013678
low	0.54	62.3	0.13	0.069	0.092
medium	0.53	62.3	0.13	0.080	0.17*
high	0.49*	62.7	0.12	0.081	0.27*

Supplementary Table 5. Contributing study by calibration group. Cross-tabulation of contributing study (18 in total) and calibration group. No statistically significant association (p=0.05) between the two variables was found.

		Contributing Study					
		BioVU	CeRePP	CPDR	EPICAP	KARUPROSTATE	
	low	78	44	62	8	240	
	medium	64	61	61	13	276	
	high	62	80	53	8	233	
		MIAMI- WFPCS	MOFFITT	NMHS	PCaP	PROtEuS	
0	low	28	57	136	349	41	
no.	medium	37	61	119	332	36	
n gr	high	43	74	109	286	46	
Calibration group		SABOR	SCCS	SCPCS	SFPCS	SWOG-PCPT	
Sali	low	70	568	26	38	57	
O	medium	78	586	30	46	59	
	high	63	635	33	33	48	
		SWOG- SELECT	UKGPCS	WUGS	_		
	low	70	127	64			
	medium	66	123	79			
	high	61	115	81			

Supplementary Table 6. Standardized chi-squared residuals. Standardized residuals of the chi-squared test between continental and calibration groups in the 1000 Genomes dataset are tabulated. The largest contribution to the statistically significant chi-squared value was a result of the greater-than-expected number of Africans within the low-calibration group.

		Calibration group		
	_	low	middle	high
Continental group	African	14.3	-8.8	-8.7
	American	-7.9	5.6	3.7
	Asian	2.7	-1.2	-2.4
	European	-7.7	4.3	5.4
	South Asian	-4.0	1.8	3.3

Supplementary Table 7. Cross-tabulation of continental and calibration groups. Cross-tabulation of continental and calibration groups by calibration group (column sum equals 1), and by continental group (row sum equals 1). Values are expressed as percentages.

By calibration group		Calibration group				
		low	middle	high		
Continental group	African	38.8	16.1	6.5		
	American	8.5	19.0	20.5		
	Asian	22.3	18.9	15.2		
	European	14.0	24.6	31.4		
	South Asian	16.4	21.4	26.4		
By continental group		Calibration group				
		low	middle	high		
Continental group	African	74.6	22.2	3.2		
	American	31.1	49.9	19.0		
	Asian	56.2	34.1	9.7		
	European	35.4	44.5	20.1		
	South Asian	42.7	39.9	17.4		

Appendix 1. Members of the PRACTICAL Consortium

Christopher A. Haiman¹, Fredrick R. Schumacher^{2,3}, Sara Benlloch^{4,5}, Ali Amin Al Olama^{6,7}, Sonja I. Berndt⁸, David V. Conti¹, Fredrik Wiklund⁹, Stephen Chanock⁸, Susan M. Gapstur¹⁰, Victoria L. Stevens¹⁰, Jyotsna Batra^{11,12}, Judith Clements^{11,12}, APCB BioResource^{13,14}, Henrik Grönberg¹⁵, Nora Pashayan^{16,17}, Johanna Schleutker^{18,19}, Demetrius Albanes⁸, Stephanie Weinstein⁸, Alicja Wolk^{20,21}, Catharine West²², Lorelei Mucci²³, Stella Koutros⁸, Karina Dalsgaard Sørensen^{24,25}, Eli Marie Grindedal²⁶, David E. Neal^{27,28,29}, Freddie C. Hamdy^{30,31}, Jenny L. Donovan³², Ruth C. Travis³³, Robert J. Hamilton^{34,35}, Sue Ann Ingles³⁶, Barry S. Rosenstein^{37,38}, Yong-Jie Lu³⁹, Graham G. Giles^{40,41,42}, Ana Vega^{43,44,45}, Manolis Kogevinas^{46,47,48,49}, Kathryn L. Penney⁵⁰, Janet L. Stanford^{51,52}, Cezary Cybulski⁵³, Børge G. Nordestgaard^{54,55}, Hermann Brenner^{56,57,58}, Christiane Maier⁵⁹, Jeri Kim⁶⁰, Manuel R. Teixeira^{61,62}, Susan L. Neuhausen⁶³, Kim De Ruyck⁶⁴, Azad Razack⁶⁵, Lisa F. Newcomb^{51,66}, Davor Lessel⁶⁷, Radka Kaneva⁶⁸, Nawaid Usmani^{69,70}, Frank Claessens⁷¹, Paul A. Townsend⁷², Manuela Gago-Dominguez^{73,74}, Monique J. Roobol⁷⁵, Kay-Tee Khaw⁷⁶, Lisa Cannon-Albright^{77,78}, Hardev Pandha⁷⁹, Stephen N. Thibodeau⁸⁰, Peter Kraft⁸¹, Elio Riboli⁸²

¹Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA

²Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106-7219, USA

³Seidman Cancer Center, University Hospitals, Cleveland, OH 44106, USA.

⁴Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK ⁵The Institute of Cancer Research, London, SM2 5NG, UK

⁶Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK

⁷University of Cambridge, Department of Clinical Neurosciences, Stroke Research Group, R3, Box 83, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK

⁸Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, 20892, USA

⁹Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden

¹⁰Behavioral and Epidemiology Research Group, Research Program, American Cancer

Society, 250 Williams Street, Atlanta, GA 30303, USA

- ¹¹Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane QLD 4059, Australia
- ¹²Translational Research Institute, Brisbane, Queensland 4102, Australia
- ¹³Australian Prostate Cancer Research Centre-Qld, Queensland University of Technology, Brisbane; Prostate Cancer Research Program, Monash University, Melbourne; Dame Roma Mitchell Cancer Centre, University of Adelaide, Adelaide; Chris O'Brien Lifehouse and
- ¹⁴Translational Research Institute, Brisbane, Queensland, Australia
- ¹⁵Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- ¹⁶Department of Applied Health Research, University College London, London, WC1E 7HB, UK
- ¹⁷Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK
- ¹⁸Institute of Biomedicine, Kiinamyllynkatu 10, FI-20014 University of Turku, Finland
- ¹⁹Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, PO Box 52, 20521 Turku, Finland
- ²⁰Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm. Sweden
- ²¹Department of Surgical Sciences, Uppsala University, 75185 Uppsala, Sweden
- ²²Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester, M13 9PL UK
- ²³Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA
- ²⁴Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensen Boulevard 99, 8200 Aarhus N, Denmark
- ²⁵Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N
- ²⁶Department of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway
- ²⁷Nuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK
- ²⁸University of Cambridge, Department of Oncology, Box 279, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK
- ²⁹Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge UK

- ³⁰Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX1 2JD, UK
- ³¹Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK
- ³²Population Health Sciences, Bristol Medical School, University of Bristol, BS8 2PS, UK
- ³³Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK
- ³⁴Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto ON M5G 2M9, Canada
- ³⁵Dept. of Surgery (Urology), University of Toronto, Canada
- ³⁶Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA
- ³⁷Department of Radiation Oncology and Department of Genetics and Genomic Sciences, Box 1236, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA
- ³⁸Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-5674, USA.
- ³⁹Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK
- ⁴⁰Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC 3004, Australia
- ⁴¹Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia
- ⁴²Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria 3168, Australia
- ⁴³Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, 15706, Spain.
- ⁴⁴Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, 15706, Spain.
- ⁴⁵Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain
- ⁴⁶ISGlobal, Barcelona, Spain
- ⁴⁷IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- ⁴⁸Universitat Pompeu Fabra (UPF), Barcelona, Spain
- ⁴⁹CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- ⁵⁰Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02184, USA
- ⁵¹Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle,

- Washington, 98109-1024, USA
- ⁵²Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington 98195, USA
- ⁵³International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
- ⁵⁴Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
- ⁵⁵Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2200 Copenhagen, Denmark
- ⁵⁶Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120, Heidelberg, Germany
- ⁵⁷German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany
- ⁵⁸Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460 69120 Heidelberg, Germany
- ⁵⁹Humangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076 Tuebingen, Germany
- ⁶⁰The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1515 Holcombe Blvd., Houston, TX 77030, USA
- ⁶¹Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal
- ⁶²Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal
- ⁶³Department of Population Sciences, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, 626-256-HOPE (4673)
- ⁶⁴Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, Proeftuinstraat 86, B-9000 Gent
- ⁶⁵Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
- ⁶⁶Department of Urology, University of Washington, 1959 NE Pacific Street, Box 356510, Seattle, WA 98195, USA
- ⁶⁷Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany
- ⁶⁸Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria
- ⁶⁹Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University

Avenue, Edmonton, Alberta, Canada T6G 1Z2

⁷⁰Division of Radiation Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada T6G 1Z2

⁷¹Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE-3000, Belgium

 ⁷²Division of Cancer Sciences, Manchester Cancer Research Centre, Faculty of Biology,
Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester
Biomedical Research Centre, Health Innovation Manchester, University of Manchester, M13
9WL

 ⁷³Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS, 15706, Santiago de Compostela, Spai
⁷⁴University of California San Diego, Moores Cancer Center, La Jolla, CA 92037, USA
⁷⁵Department of Urology, Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands

⁷⁶Clinical Gerontology Unit, University of Cambridge, Cambridge, CB2 2QQ, UK

⁷⁷Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA

⁷⁸George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah 84148, USA

⁷⁹The University of Surrey, Guildford, Surrey, GU2 7XH

⁸⁰Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA

⁸¹Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA

⁸²Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, SW7 2AZ, UK

Appendix 2. Funding sources for the PRACTICAL consortium

CRUK and PRACTICAL consortium

This work was supported by the Canadian Institutes of Health Research, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall's. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I].

This study would not have been possible without the contributions of the following: Coordination team, bioinformatician and genotyping centers: Genotyping at CCGE, Cambridge: Caroline Baines and Don Conroy

Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174,

C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

This study would not have been possible without the contributions of the following: Per Hall (COGS); Douglas F. Easton, Paul Pharoah, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang (BCAC), Andrew Berchuck (OCAC), Rosalind A. Eeles, Douglas F. Easton, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Joe Dennis, Alison M. Dunning, Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility

Additional funding and acknowledgments from studies in PRACTICAL:

Information of the PRACTICAL consortium can be found at http://practical.icr.ac.uk/

BioVU

The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU, which is supported by institutional funding and by the National Center for Research Resources, Grant UL1 RR024975-01 (which is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06).

CPDR

Uniformed Services University for the Health Sciences HU0001-10-2-0002 (PI: David G. McLeod, MD)

EPICAP

The EPICAP study was supported by grants from Ligue Nationale Contre le Cancer; Institut

National du Cancer (INCa): Fondation ARC; Fondation de France; Agence Nationale de

sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES); Ligue

départementale du Val de Marne. The EPICAP study group would like to thank all urologists,

Antoinette Anger and Hasina Randrianasolo (study monitors), Anne-Laure Astolfi, Coline

Bernard, Oriane Noyer, Marie-Hélène De Campo, Sandrine Margaroline, Louise N'Diaye,

Sabine Perrier-Bonnet (Clinical Research nurses)

KARUPROSTATE

The Karuprostate study was supported by the the Frech National Health Directorate, the

Association pour la Recherche sur le Cancer, la Lique Nationale contre le Cancer, the French

Agency for Environmental and Occupational Health Safety (ANSES) and by the Association

pour la Recherche sur les Tumeurs de la Prostate. We would like to thank Séverine Ferdinand

for valuable contributions to the study.

MOFFITT

The Moffitt group was supported by the US National Cancer Institute (R01CA128813, PI: J.Y.

Park).

NMHS

Funding for the Nashville Men's Health Study (NMHS) was provided by the National Institutes of

Health Grant numbers: RO1CA121060

PCaP

The North Carolina - Louisiana Prostate Cancer Project (PCaP) and the Health Care Access

and Prostate Cancer Treatment in North Carolina (HCaP-NC) study are carried out as

collaborative studies supported by the Department of Defense contract DAMD 17-03-2-0052

and the American Cancer Society award RSGT-08-008-01-CPHPS, respectively.

The authors thank the staff, advisory committees and research subjects participating in the

PCaP and HCaP-NC studies for their important contributions.

PROtEuS

23

PROtEuS was supported financially through grants from the Canadian Cancer Society [13149, 19500, 19864, 19865] and the Cancer Research Society, in partnership with the Ministère de l'enseignement supérieur, de la recherche, de la science et de la technologie du Québec, and the Fonds de la recherche du Québec - Santé.PROtEuS would like to thank its collaborators and research personnel, and the urologists involved in subjects recruitment. We also wish to acknowledge the special contribution made by Ann Hsing and Anand Chokkalingam to the conception of the genetic component of PROtEuS.

SABOR

The SABOR research is supported by NIH/NCI Early Detection Research Network, grant U01 CA0866402-18. Also supported by the Cancer Center Support Grant to the Mays Cancer Center from the National Cancer Institute (US) P30 CA054174

SCCS

SCCS is funded by NIH grant R01 CA092447, and SCCS sample preparation was conducted at the Epidemiology Biospecimen Core Lab that is supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA68485). Data on SCCS cancer cases used in this publication were provided by the Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer Registry, 4815 W. Markham, Little Rock, AR 72205. The Arkansas Central Cancer Registry is fully funded by a grant from National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected by the Mississippi Cancer Registry which participates in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi Cancer Registry.

SCPCS

SCPCS is funded by CDC grant S1135-19/19, and SCPCS sample preparation was conducted at the Epidemiology Biospecimen Core Lab that is supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA68485).

SFPCS

SFPCS was funded by California Cancer Research Fund grant 99-00527V-10182

SWOG-PCPT / SWOG-SELECT

PCPT and SELECT are funded by Public Health Service grants U10CA37429 and 5UM1CA182883 from the National Cancer Institute. The authors thank the site investigators and staff and, most importantly, the participants from PCPT who donated their time to this trial.

UKGPCS

UKGPCS would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. UKGPCS should also like to acknowledge the NCRN nurses, data managers and Consultants for their work in the UKGPCS study.UKGPCS would like to thank all urologists and other persons involved in the planning, coordination, and data collection of the study. KM and AL were in part supported from the NIHR Manchester Biomedical Research Centre

WUGS

WUGS would like to thank the following for funding support: The Anthony DeNovi Fund, the Donald C. McGraw Foundation, and the St. Louis Men's Group Against Cancer.